BR112021019189A2 - Antagonistas do receptor de acetilcolina muscarínico subtipo 4 no tratamento de anemia - Google Patents
Antagonistas do receptor de acetilcolina muscarínico subtipo 4 no tratamento de anemiaInfo
- Publication number
- BR112021019189A2 BR112021019189A2 BR112021019189A BR112021019189A BR112021019189A2 BR 112021019189 A2 BR112021019189 A2 BR 112021019189A2 BR 112021019189 A BR112021019189 A BR 112021019189A BR 112021019189 A BR112021019189 A BR 112021019189A BR 112021019189 A2 BR112021019189 A2 BR 112021019189A2
- Authority
- BR
- Brazil
- Prior art keywords
- anemia
- treatment
- subtype
- acetylcholine receptor
- muscarinic acetylcholine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019189A2 true BR112021019189A2 (pt) | 2021-11-30 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019189A BR112021019189A2 (pt) | 2019-03-25 | 2020-03-20 | Antagonistas do receptor de acetilcolina muscarínico subtipo 4 no tratamento de anemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497411B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946321A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7558187B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102914803B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613650B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020247812B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132381A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286617A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011588A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109857UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198054A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649626A (en) * | 1970-04-27 | 1972-03-14 | Warner Lambert Co | Fused ring systems containing (1 3)oxazine |
| DK1282625T3 (da) * | 2000-05-09 | 2004-11-15 | Warner Lambert Co | Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom |
| CA2357306A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| US8329689B2 (en) * | 2006-05-23 | 2012-12-11 | Alexandre Vasilievich Ivachtchenko | Substituted indoles and a method for the production and use thereof |
| US20130059783A1 (en) * | 2010-03-12 | 2013-03-07 | Johan Flygare | Compositions and methods for expanding bfu-e cells |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
-
2020
- 2020-03-20 CN CN202080024089.9A patent/CN113613650B/zh active Active
- 2020-03-20 JP JP2021553300A patent/JP7558187B2/ja active Active
- 2020-03-20 AU AU2020247812A patent/AU2020247812B2/en active Active
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 KR KR1020217029823A patent/KR102914803B1/ko active Active
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en not_active Ceased
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/es unknown
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/pt unknown
- 2020-03-20 US US17/442,926 patent/US12497411B2/en active Active
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
-
2024
- 2024-05-20 JP JP2024081788A patent/JP2024102364A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109857UA (en) | 2021-10-28 |
| IL286617A (en) | 2021-10-31 |
| KR102914803B1 (ko) | 2026-01-20 |
| CA3132381A1 (en) | 2020-10-01 |
| EP3946321A4 (en) | 2023-03-08 |
| JP2024102364A (ja) | 2024-07-30 |
| JP2022525293A (ja) | 2022-05-12 |
| MX2021011588A (es) | 2021-12-15 |
| CN113613650B (zh) | 2024-12-10 |
| AU2020247812B2 (en) | 2025-09-11 |
| KR20210144697A (ko) | 2021-11-30 |
| AU2020247812A1 (en) | 2021-09-30 |
| JP7558187B2 (ja) | 2024-09-30 |
| US20220185821A1 (en) | 2022-06-16 |
| CN113613650A (zh) | 2021-11-05 |
| WO2020198054A1 (en) | 2020-10-01 |
| EP3946321A1 (en) | 2022-02-09 |
| US12497411B2 (en) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500509A1 (en) | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | |
| CL2008000212A1 (es) | Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre | |
| BR112018075166A2 (pt) | derivados de carbonucleosídeo substituídos úteis como agentes anticâncer | |
| PH12017500507A1 (en) | Cytotoxicity-inducing therapeutic agent | |
| MD3405471T2 (ro) | Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin | |
| ECSP066669A (es) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos | |
| JO3674B1 (ar) | مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| MX2009010047A (es) | Compuestos quimicos. | |
| MX2009010045A (es) | Compuestos quimicos. | |
| EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
| NZ590650A (en) | Buprenorphine analogs | |
| BR112017009194A2 (pt) | tetra-hidropiranos substituídos e método de uso | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| TW200800967A (en) | Benzimidazole thiophene compounds | |
| DE602008005928D1 (de) | 1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit | |
| MY148948A (en) | Catecholamine derivatives and prodrugs thereof | |
| MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| MX2020001979A (es) | Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma. | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
| UY37250A (es) | Derivados macrocíclicos de indol | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| ATE524446T1 (de) | Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |